company background image
PGEN

PrecigenNasdaqGS:PGEN Stock Report

Market Cap

US$814.5m

7D

0%

1Y

-53.1%

Updated

08 Dec, 2021

Data

Company Financials +
PGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PGEN Stock Overview

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States.

Precigen Competitors

Amgen

NasdaqGS:AMGN

US$119.0b

Gilead Sciences

NasdaqGS:GILD

US$87.4b

Incyte

NasdaqGS:INCY

US$14.7b

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$607.6m

Price History & Performance

Summary of all time highs, changes and price drops for Precigen
Historical stock prices
Current Share PriceUS$3.94
52 Week HighUS$11.10
52 Week LowUS$3.42
Beta2.29
1 Month Change-22.90%
3 Month Change-35.94%
1 Year Change-53.10%
3 Year Change-55.33%
5 Year Change-86.28%
Change since IPO-84.07%

Recent News & Updates

Aug 12
Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Shareholders in Precigen, Inc. ( NASDAQ:PGEN ) may be thrilled to learn that the analysts have just delivered a major...

Shareholder Returns

PGENUS BiotechsUS Market
7D0%-2.5%1.7%
1Y-53.1%-2.2%19.8%

Return vs Industry: PGEN underperformed the US Biotechs industry which returned -2.2% over the past year.

Return vs Market: PGEN underperformed the US Market which returned 19.8% over the past year.

Price Volatility

Is PGEN's price volatile compared to industry and market?
PGEN volatility
PGEN Average Weekly Movement8.7%
Biotechs Industry Average Movement9.0%
Market Average Movement6.2%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: PGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PGEN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998450Helen Sabzevarihttps://www.precigen.com

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium.

Precigen Fundamentals Summary

How do Precigen's earnings and revenue compare to its market cap?
PGEN fundamental statistics
Market CapUS$814.55m
Earnings (TTM)-US$111.41m
Revenue (TTM)US$98.99m

8.2x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PGEN income statement (TTM)
RevenueUS$98.99m
Cost of RevenueUS$105.04m
Gross Profit-US$6.06m
ExpensesUS$105.36m
Earnings-US$111.41m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-6.12%
Net Profit Margin-112.56%
Debt/Equity Ratio137.3%

How did PGEN perform over the long term?

See historical performance and comparison

Valuation

Is Precigen undervalued compared to its fair value and its price relative to the market?

6.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PGEN is overvalued based on its PB Ratio (6.2x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Precigen forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

0.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PGEN's revenue (12.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: PGEN's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PGEN is forecast to be unprofitable in 3 years.


Past Performance

How has Precigen performed over the past 5 years?

4.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PGEN is currently unprofitable.

Growing Profit Margin: PGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: PGEN has a negative Return on Equity (-84.89%), as it is currently unprofitable.


Financial Health

How is Precigen's financial position?


Financial Position Analysis

Short Term Liabilities: PGEN's short term assets ($153.1M) exceed its short term liabilities ($29.0M).

Long Term Liabilities: PGEN's short term assets ($153.1M) do not cover its long term liabilities ($216.7M).


Debt to Equity History and Analysis

Debt Level: PGEN's net debt to equity ratio (50.1%) is considered high.

Reducing Debt: PGEN's debt to equity ratio has increased from 1.5% to 137.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PGEN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 14% each year.


Dividend

What is Precigen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Helen Sabzevari (59 yo)

1.92yrs

Tenure

US$20,409,916

Compensation

Dr. Helen Sabzevari, Ph D., MPH, serves as Director at Kinnate Biopharma Inc. since June 2021. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation) since Janu...


CEO Compensation Analysis

Compensation vs Market: Helen's total compensation ($USD20.41M) is above average for companies of similar size in the US market ($USD2.31M).

Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PGEN's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: PGEN's board of directors are seasoned and experienced ( 10.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PGEN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.


Top Shareholders

Company Information

Precigen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Precigen, Inc.
  • Ticker: PGEN
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$814.550m
  • Shares outstanding: 206.74m
  • Website: https://www.precigen.com

Number of Employees


Location

  • Precigen, Inc.
  • 20374 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/08 00:52
End of Day Share Price2021/12/07 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.